This study was carried out to investigate the clinical effects of Tongbiyeum(TBY) ₂on hyperlipidemia. The hyperlipidemia of rats was induced by feeding high cholesterol diet for 4 weeks. We checked serum lipids and body weight weekly for 4 weeks. After the termination of treatment, we measured liver weight and observed histopathological change. We compared result of TBY group with control group. Thereafter, we made a study of 37 hyperlipidemic patients who visited us, the oriental medical center Daejeon and cheongju of Daejeon University, from November, 2001 to April, 2002. After administering TBY for 1 month, we followed up their total cholesterol, triglyceride and HDL-Cholesterol levels. The results were as follows; TBY treatment inhibited the liver weight gain induced by high cholesterol diet as compared with control group. TBY treatment inhibited lipid droplet accumulation and apoptotic change in liver as compared with control group. TBY treatment significantly inhibited the increasing of serum triglyceride and total cholesterol levels induced by high cholesterol diet as compared with control group but not affect HDL-cholesterol level. After administering TBY, the serum total cholesterol, triglyceride and LDL-cholesterol levels of hyperlipidemic patients were decreased significantly. After administering TBY, the serum HDL-Cholesterol level of hyperlipidemic patients had no significant changes. According to above mentioned results, we can infer that TBY has hypolipidemic effect to be applicable to artheriosclerosis.